A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma (NCT07116616)
A Phase 1/2, Open-label, Multicenter Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham Hospital — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- University of Alabama at Birmingham Hospital — Birmingham, Alabama
- UCSF — San Francisco, California
- Emory University Hospital — Atlanta, Georgia
- Mass General Brigham — Boston, Massachusetts
- Tisch Cancer Institute at Mount Sinai — New York, New York
- Memorial Sloan-Kettering Cancer Center — New York, New York
- Atrium Health Levine Cancer Institute — Charlotte, North Carolina
- Penn Medicine — Philadelphia, Pennsylvania
- Sarah Cannon Research Institute — Nashville, Tennessee
- The Medical College of Wisconsin — Milwaukee, Wisconsin
📞 Contact the Study Coordinator
Phone: (866) 663-3762
Email: WeCareClinicalTrials@modernatx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapsed or Refractory Multiple Myeloma
- A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) — Mobile, Alabama
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma — Anchorage, Alaska
- A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma — Toronto, Ontario
- A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma — Tucson, Arizona
- A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma — Duarte, California
Explore by condition: All Relapsed or Refractory Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.